System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Ornella Garrone is an expert in Oncology at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Italy). As of October 2026, ScienceLeadR ranks Ornella Garrone in the top 1% of experts worldwide for Breast Neoplasms and Breast Diseases. Ornella Garrone has authored 334 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 5 of them ongoing. SLR score: 1,088 (community average: 125). How the SLR is computed.

LeadR Profile

Ornella Garrone Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Italy
1 088 ScienceLeadR Reputation 1088

Unlock

Register Login
Network Map

Oncology

Subspecialties: Biochemistry - Public Health - Dermatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2019 - 2026
Source: PubMed

Associazione Italiana Di Oncologia Medica

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 334

Citations

Citations: 6 641 1st author: 34 Last author: 37 Unique author: 0

Main journals

Ann Oncol 49
J Clin Oncol 47
Cancer Res 20
ESMO Open 16
Eur J Cancer 16

Best Journals

Ann Oncol 17
J Clin Oncol 13
JAMA 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Fertility Treatment and Risk of Melanoma: A Certainty-Rated Systematic Review and Meta-Analysis of 3,733,499 Women.
PMID 42924873 — bias, fertility, incidence, pharmaceutical preparations, melanoma, therapeutics		Eur J Clin Invest20260
Prognostic value of hormone receptor expression in patients with HR+/HER2- advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study.
PMID 42872060 — hormones, therapeutics		EClinicalMedicine20260
Management of Melanoma in Advanced Age: A Comprehensive Literature Review of Tumor Biology, Systemic Therapies and Geriatric Challenges.
PMID 42795023 — comorbidity, safety, incidence, melanoma, neoplasms, aged, therapeutics		Cancers (Basel)20260
Intracellular Nanopharmacology of Trastuzumab Deruxtecan Reveals Lysosome-Centered Organelle Vulnerabilities in HER2-Positive Breast Cancer Cells.
PMID 42729999 — organelles, cells, breast neoplasms, nanoparticles, pharmaceutical preparations, stress, physiological, neoplasms, mitochondria, microscopy, electron, breast, lysosomes, trastuzumab		ACS Nano Med20260
Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.
PMID 42685569 — breast neoplasms, neoplasms, breast, therapeutics		Eur J Cancer20261

Clinical Studies 16

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2 Study Chair: 1

By phase:

N/A 6
Phase 3 6
Phase 2 3
Phase 4 1

By status:

Recruiting 6
Completed 4
Active not recruiting 2
Unknown 2
Not yet recruiting 1
Terminated 1

By type:

Interventional 13
Observational 3

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 1
multicentric5to9 2
multicentricup10 8

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A proof of concept study to evaluate treatments efficacy by monitoring Minimal Residual Disease using ctDNA in HR positive HER2 negative early breast cancer population
2023-505661-89-00 — epidermal growth factor, growth, breast neoplasms, neoplasms, hormones, proof of concept study, receptors, growth factor, breast, neoplasm, residual, therapeutics		Phase 2Recruiting2024
Physical Activity and Healthy Aging Promoting Cardio metabolic Capacity to Fight Chronic Inflammation and Improve Outcomes in Breast Cancer Patients (PhActHealth Study)
NCT07776951 — exercise, triple negative breast neoplasms, exercise tolerance, life style, breast neoplasms, heart rate, heart, aging, neoplasms, recycling, motor activity, breast, neoadjuvant therapy, therapeutics, resistance training, healthy aging		N/ARecruiting2026
Extracellular Vesicles and Chemotherapy Induced Peripheral Neuropathy
NCT07558447 — extracellular vesicles, lung, antimitotic agents, peripheral nervous system diseases, blood, breast neoplasms, docetaxel, paclitaxel, pharmaceutical preparations, micrornas, neurotoxicity syndromes, neoplasms, biopsy, drug therapy, oxaliplatin, gastrointestinal neoplasms, biomarkers, urologic neoplasms, signs and symptoms, lung neoplasms, breast, membrane lipids, physicians, head and neck neoplasms, therapeutics, capecitabine, carboplatin, liquid biopsy, membranes, chemotherapy, lipids, head, neck		N/ARecruiting2025
Predicting clinicAL outcoMes During First line CDK4 6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor poSitive HER2 negative Breast Cancer the Retrospective prospective Multicenter Italian PALMARES 2 Study
NCT06805812 — breast neoplasms, male, blood, breast neoplasms, lymphocytes, cyclin-dependent kinase 4, data collection, neoplasms, adenocarcinoma, bone diseases, hormones, cyclin-dependent kinases, cyclins, breast, therapeutics, mutation, breast diseases, carcinoma, male, men, bone and bones		N/ARecruiting2023
CHEmotherapy and Cognitive Deterioration in Patients With Operable Breast Cancer Impact of Cognitive Rehabilitation (CHEMOFOG)
NCT06435559 — breast neoplasms, neoplasms, rehabilitation, executive function, cognitive dysfunction, drug therapy, chemotherapy, adjuvant, breast, cognition disorders, therapeutics, learning, chemotherapy-related cognitive impairment, memory, chemotherapy, cognitive training, carcinoma		N/ANot yet recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS